The Pancreatic Cancer Detection Consortium (PCDC) develops and tests new molecular and imaging biomarkers to detect early stage pancreatic ductal adenocarcinoma (PDAC) and its precursor lesions. These biomarkers would be used to identify individuals who are at high risk of developing PDAC and are candidates for early intervention.
Read more About PCDC.
Teams
- Beckman Research Institute, City of Hope Comprehensive Cancer Center/Translational Genomics Research Institute
- Dana Farber Cancer Institute/Harvard Medical School
- Johns Hopkins University
- Mayo Clinic/University of Pennsylvania
- Stanford University
- The University of Texas MD Anderson Cancer Center
- University of California, Davis
- University of Nebraska Medical Center
PCDC Resources and Collaborative Opportunities
- Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC)
- Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection
Read more about PCDC Resources and Collaborative Opportunities
Administration
- Structure
- Steering Committee
- Consortium Coordinator
- NCI Program Staff
The Search for Early Detection of Pancreatic Cancer Accelerates with Biomarkers
Scientists have identified more than 1,000 potential new biomarkers for cancer that they hope will aid in the early detection of many of these complex diseases, including one of the most challenging, pancreatic cancer.
Pancreatic Cysts Are Monitored in New Trial Aimed at Reducing Cancer Risk Through Targeted Screening
In a new NCI-sponsored study now recruiting participants, investigators will evaluate two different screening strategies for non-cancerous pancreatic cysts to determine which works best at detecting early malignancy.
New Onset Diabetes Cohort Sought to Unravel Complexities of Pancreatic Cancer Development
The National Cancer Institute is leading a project to create a cohort of people who are newly diagnosed with diabetes in the hopes that this group, who are at increased risk of developing pancreatic cancer, provide the clues in their blood and tissues to unravel some of the unknowns about this highly fatal cancer. The New Onset Diabetes Study (NOD) will include 10,000 people ages 50 to 85...